SCIMP

Summary

SCIMP (SLP adaptor and CSK interacting membrane protein, HGNC:33504) is a protein-coding gene on chromosome 17p13.2, encoding SLP adapter and CSK-interacting membrane protein (Q6UWF3). Lipid tetraspanin-associated transmembrane adapter/mediator that acts as a scaffold for Src-family kinases and other signaling proteins in immune cells.

This gene encodes a transmembrane adaptor protein that is expressed in antigen-presenting cells and is localized in the immunologic synapse. The encoded protein is involved in major histocompatibility complex class II signal transduction and immune synapse formation. Alternatively spliced transcript variants have been found for this gene.

Source: NCBI Gene 388325 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 25 total
• Druggable target: yes
• MANE Select transcript: NM_207103

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:33504
Approved symbol	SCIMP
Name	SLP adaptor and CSK interacting membrane protein
Location	17p13.2
Locus type	gene with protein product
Status	Approved
Aliases	DTFT5783, UNQ5783, FLJ32580, MGC163426, MGC163428
Ensembl gene	ENSG00000161929
Ensembl biotype	protein_coding
OMIM	614406
Entrez	388325

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000399600, ENST00000571800, ENST00000574081, ENST00000574297

RefSeq mRNA: 3 — MANE Select: NM_207103 NM_001271842, NM_001319190, NM_207103

CCDS: CCDS42242, CCDS62044, CCDS82046

Canonical transcript exons

ENST00000574081 — 5 exons

Exon	Start	End
ENSE00001274411	5214925	5214998
ENSE00001736749	5221287	5221350
ENSE00002229633	5234735	5234860
ENSE00002385282	5223333	5223456
ENSE00002662083	5208920	5210955

Expression profiles

Bgee: expression breadth ubiquitous, 133 present calls, max score 97.90.

FANTOM5 (CAGE): breadth broad, TPM avg 11.0964 / max 600.9318, expressed in 394 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
164022	10.4353	391
164021	0.5917	143
164023	0.0694	38

Top tissues by expression

136 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	97.90	gold quality
leukocyte	CL:0000738	97.75	gold quality
granulocyte	CL:0000094	94.73	gold quality
spleen	UBERON:0002106	91.34	gold quality
thymus	UBERON:0002370	91.22	silver quality
lymph node	UBERON:0000029	91.17	gold quality
vermiform appendix	UBERON:0001154	91.15	gold quality
blood	UBERON:0000178	88.55	gold quality
cerebellar vermis	UBERON:0004720	86.77	gold quality
quadriceps femoris	UBERON:0001377	84.34	gold quality
tonsil	UBERON:0002372	76.68	gold quality
gall bladder	UBERON:0002110	75.89	gold quality
smooth muscle tissue	UBERON:0001135	74.47	gold quality
duodenum	UBERON:0002114	73.82	gold quality
small intestine Peyer’s patch	UBERON:0003454	73.56	gold quality
rectum	UBERON:0001052	73.31	gold quality
small intestine	UBERON:0002108	73.21	gold quality
placenta	UBERON:0001987	72.35	gold quality
upper lobe of left lung	UBERON:0008952	71.79	gold quality
lung	UBERON:0002048	71.74	gold quality
right lung	UBERON:0002167	71.61	gold quality
bone marrow	UBERON:0002371	71.01	gold quality
bone marrow cell	CL:0002092	70.92	gold quality
liver	UBERON:0002107	70.55	gold quality
right adrenal gland cortex	UBERON:0035827	69.01	gold quality
right adrenal gland	UBERON:0001233	68.89	gold quality
mucosa of transverse colon	UBERON:0004991	68.46	gold quality
descending thoracic aorta	UBERON:0002345	67.60	gold quality
left adrenal gland	UBERON:0001234	67.35	gold quality
adrenal gland	UBERON:0002369	67.31	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-MTAB-8498	yes	310.37
E-GEOD-75367	yes	106.37
E-CURD-122	yes	24.58
E-ANND-3	yes	21.37
E-GEOD-70580	no	68.99

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

69 targeting SCIMP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-3912-5P	99.95	66.11	925
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-6794-5P	99.76	66.38	1048
HSA-MIR-1197	99.70	67.75	1027
HSA-MIR-4716-3P	99.69	66.73	1022
HSA-MIR-4502	99.65	66.99	1021
HSA-MIR-4762-5P	99.57	68.54	1424
HSA-MIR-4328	99.57	71.06	4094
HSA-MIR-4753-5P	99.54	68.51	1356
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-671-5P	99.52	67.11	1277
HSA-MIR-889-3P	99.40	69.76	2103
HSA-MIR-19A-5P	99.36	66.93	1675
HSA-MIR-19B-1-5P	99.36	67.07	1669

Literature-anchored findings (GeneRIF, showing 2)

• results suggest that SCIMP is involved in signal transduction after MHC-II stimulation and therefore serves as a regulator of antigen presentation and other APC functions. (PMID:21930792)
• SCIMP: A Novel Targeted Gene for Postmenopausal Osteoporosis Progression. (PMID:37057624)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Scimp	ENSMUSG00000057135
rattus_norvegicus	Scimp	ENSRNOG00000037409

Paralogs (2): BCL2L11 (ENSG00000153094), MEI1 (ENSG00000167077)

Protein

Protein identifiers

SLP adapter and CSK-interacting membrane protein — Q6UWF3 (reviewed: Q6UWF3)

Alternative names: SLP65/SLP76, Csk-interacting membrane protein

All UniProt accessions (2): Q6UWF3, I3L1W2

UniProt curated annotations — full annotation on UniProt →

Function. Lipid tetraspanin-associated transmembrane adapter/mediator that acts as a scaffold for Src-family kinases and other signaling proteins in immune cells. It is involved in major histocompatibility complex class II (MHC-II) signaling transduction in B cells, where it is required in generating the calcium response and enhancing ERK activity upon MHC-II stimulation. In dendritic cells, it is involved in sustaining CLEC7A/DECTIN1 signaling after CLEC7A activation by fungal beta-glucans. It also acts as an agonist-inducible signaling adapter for TLR1, TLR2, TLR3, TLR4, and TLR7 by selectively enabling the expression of pro-inflammatory cytokines IL6 and IL12B in macrophages and acting as a scaffold for phosphorylation of Toll-like receptors by Src-family kinases.

Subunit / interactions. Interacts with CD37, CD53 and CD81. Interacts (via proline-rich region) with LYN (via SH3 domain). Interacts with CSK (via SH2 domain); this interaction is dependent on phosphorylation of Tyr-107. Interacts with BLNK (via SH2 domain); this interaction is dependent on phosphorylation of Tyr-131. Interacts with GRB2 (via SH2 domain); this interaction may be dependent on phosphorylation of Tyr-69. Interacts with TLR4; this interaction occurs upon lipopolysaccharide activation of TLR4 and is enhanced by phosphorylation of Tyr-107 by LYN. This interaction facilitates the phosphorylation of TLR4 by LYN which elicits a selective cytokine response in macrophages.

Subcellular location. Cell membrane. Cytoplasmic vesicle. Phagosome. Cell projection. Ruffle. Filopodium.

Tissue specificity. Expressed in antigen-presenting cells, like peripheral blood leukocytes and monocyte-derived dendritic cells (MDDC) (at protein level). Highly expressed in lymph nodes and spleen. Expressed in antigen-presenting cells. Faintly expressed in the majority of nonimmune system tissues.

Post-translational modifications. Phosphorylated by the Src-family protein tyrosine kinases LYN and SRC. Phosphorylation occurs on tyrosine residues upon MHC-II stimulation. Phosphorylation also occurs on tyrosine residues after activation of CLEC7A/DECTIN1 by particulate beta-glucan. Lipopolysaccharide (LPS) induces phosphorylation of Tyr-69, Tyr-107 and Tyr-131 differentially to allow temporal recruitment of effector proteins GRB2, CSK and BLNK. Phosphorylation of Tyr-69 is immediately induced by LPS stimulation and allows GRB2 to bind. Tyr-107 is phosphorylated 5 minutes after LPS stimulation, which then allows CSK to bind, followed by phosphorylation of Tyr-131 10 minutes after LPS induction, which allows BLNK to bind. Phosphorylation at Tyr-107 by LYN occurs after activation of TLR4 by lipopolysaccharide; phosphorylation enhances binding to TLR4. Palmitoylated.

Isoforms (3)

UniProt ID	Names	Canonical?
Q6UWF3-1	1	yes
Q6UWF3-2	2
Q6UWF3-3	3

RefSeq proteins (3): NP_001258771, NP_001306119, NP_996986* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR028181	SCIMP	Family
IPR052133	Immune_Signaling-Apoptosis_Reg	Family

Pfam: PF15050

UniProt features (18 total): mutagenesis site 4, modified residue 4, splice variant 3, region of interest 3, lipid moiety-binding region 2, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6UWF3-F1	66.71	0.15

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 42, 69, 76, 107, 131, 40

Mutagenesis-validated functional residues (4):

Position	Phenotype
69	inhibits interaction with grb2.
81–86	inhibits interaction with lyn.
107	inhibits interaction with csk. stimulates activation of several downstream signaling pathways.
131	inhibits interaction with blnk. inhibits activation of several downstream signaling pathways.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 133 (showing top): GOBP_REGULATION_OF_STRESS_ACTIVATED_PROTEIN_KINASE_SIGNALING_CASCADE, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOBP_CELLULAR_RESPONSE_TO_BIOTIC_STIMULUS, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_POSITIVE_REGULATION_OF_MAPK_CASCADE, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION, GOCC_RUFFLE, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_LEUKOCYTE_MEDIATED_IMMUNITY, GOBP_POSITIVE_REGULATION_OF_STRESS_ACTIVATED_PROTEIN_KINASE_SIGNALING_CASCADE, GOBP_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY, GOBP_POSITIVE_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS, GOBP_REGULATION_OF_IMMUNE_RESPONSE, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_POSITIVE_REGULATION_OF_INTERLEUKIN_12_PRODUCTION

GO Biological Process (12): positive regulation of cytokine production involved in immune response (GO:0002720), positive regulation of dendritic cell cytokine production (GO:0002732), positive regulation of lipopolysaccharide-mediated signaling pathway (GO:0031666), positive regulation of interleukin-12 production (GO:0032735), positive regulation of interleukin-6 production (GO:0032755), positive regulation of stress-activated MAPK cascade (GO:0032874), toll-like receptor 3 signaling pathway (GO:0034138), toll-like receptor 4 signaling pathway (GO:0034142), toll-like receptor 7 signaling pathway (GO:0034154), toll-like receptor TLR1:TLR2 signaling pathway (GO:0038123), positive regulation of ERK1 and ERK2 cascade (GO:0070374), cellular response to molecule of fungal origin (GO:0071226)

GO Molecular Function (2): molecular adaptor activity (GO:0060090), protein binding (GO:0005515)

GO Cellular Component (12): ruffle (GO:0001726), immunological synapse (GO:0001772), membrane (GO:0016020), filopodium (GO:0030175), leading edge membrane (GO:0031256), uropod membrane (GO:0031259), signaling receptor complex (GO:0043235), phagocytic vesicle (GO:0045335), tetraspanin-enriched microdomain (GO:0097197), plasma membrane (GO:0005886), cytoplasmic vesicle (GO:0031410), cell projection (GO:0042995)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
positive regulation of cytokine production	3
plasma membrane	3
positive regulation of MAPK cascade	2
endolysosomal toll-like receptor signaling pathway	2
binding	2
cell leading edge	2
cytokine production involved in immune response	1
positive regulation of production of molecular mediator of immune response	1
regulation of cytokine production involved in immune response	1
dendritic cell cytokine production	1
positive regulation of leukocyte mediated immunity	1
positive regulation of cytokine production involved in immune response	1
regulation of dendritic cell cytokine production	1
positive regulation of response to biotic stimulus	1
positive regulation of signal transduction	1
lipopolysaccharide-mediated signaling pathway	1
regulation of lipopolysaccharide-mediated signaling pathway	1
positive regulation of response to external stimulus	1
interleukin-12 production	1
regulation of interleukin-12 production	1
interleukin-6 production	1
regulation of interleukin-6 production	1
regulation of stress-activated MAPK cascade	1
stress-activated MAPK cascade	1
positive regulation of stress-activated protein kinase signaling cascade	1
cell surface toll-like receptor signaling pathway	1
toll-like receptor signaling pathway	1
ERK1 and ERK2 cascade	1
regulation of ERK1 and ERK2 cascade	1
response to molecule of fungal origin	1
cellular response to biotic stimulus	1
molecular_function	1
plasma membrane bounded cell projection	1
actin-based cell projection	1
uropod	1
cell projection membrane	1
cell trailing edge membrane	1
protein-containing complex	1
endocytic vesicle	1

Protein interactions and networks

STRING

588 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SCIMP	CSK	P41240	669
SCIMP	BLNK	Q8WV28	595
SCIMP	ECHDC3	Q96DC8	541
SCIMP	LYN	P07948	514
SCIMP	LCP2	Q13094	502
SCIMP	SPPL2A	Q8TCT8	482
SCIMP	ZNF232	Q9UNY5	480
SCIMP	GRB2	P29354	476
SCIMP	SORL1	Q92673	418
SCIMP	TREML2	Q5T2D2	404
SCIMP	RIN3	Q8TB24	397
SCIMP	ZCWPW1	Q9H0M4	391
SCIMP	CD2AP	Q9Y5K6	377
SCIMP	APH1B	Q8WW43	370
SCIMP	CASS4	Q9NQ75	370
SCIMP	PICALM	Q13492	370

IntAct

19 interactions, top by confidence:

A	B	Type	Score
CCDC81	SCIMP	psi-mi:“MI:0915”(physical association)	0.610
MEOX2	SCIMP	psi-mi:“MI:0915”(physical association)	0.560
SCIMP	CSK	psi-mi:“MI:0914”(association)	0.500
CSK	SCIMP	psi-mi:“MI:0915”(physical association)	0.500
SCIMP	LYN	psi-mi:“MI:0914”(association)	0.500
LYN	SCIMP	psi-mi:“MI:0915”(physical association)	0.500
CD37	SCIMP	psi-mi:“MI:0914”(association)	0.460
SCIMP	CD37	psi-mi:“MI:0914”(association)	0.460
CD53	SCIMP	psi-mi:“MI:0914”(association)	0.350
CCDC81	CD53	psi-mi:“MI:0914”(association)	0.350
SCIMP	GRB2	psi-mi:“MI:0914”(association)	0.350
SCIMP	INPPL1	psi-mi:“MI:0914”(association)	0.350
SCIMP	MEOX2	psi-mi:“MI:0915”(physical association)	0.000
SCIMP	yheS_3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (5): SCIMP (Two-hybrid), INPPL1 (Affinity Capture-MS), CCDC51 (Affinity Capture-MS), SCIMP (Cross-Linking-MS (XL-MS)), SCIMP (Affinity Capture-Luminescence)

ESM2 similar proteins: A0A1B0GRQ0, A0A1B0GVT2, A0JNM1, A2VE22, A5PLA0, B3DHW5, B4DS77, D3Z1Q2, D3ZZP4, F1M2Z5, O75264, O75324, P02725, P04921, P0C2L3, P0DKX4, P59648, P61807, P61808, Q08DP3, Q0VFL4, Q0VFM5, Q0VG18, Q13113, Q17Q87, Q28F36, Q2KIP5, Q2WFL8, Q2YDG7, Q3UU41, Q3ZBJ3, Q5RA41, Q5T1S8, Q6GM22, Q6ITQ4, Q6UWF3, Q78HU7, Q80WK2, Q86UW2, Q8BUM6

Diamond homologs: Q3UU41, Q6UWF3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

25 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	17
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

814 predictions. Top by Δscore:

Variant	Effect	Δscore
17:5214919:ACTT:A	donor_loss	1.0000
17:5214920:CTT:C	donor_loss	1.0000
17:5214921:TTA:T	donor_loss	1.0000
17:5214922:TACA:T	donor_loss	1.0000
17:5214923:A:AC	donor_gain	1.0000
17:5214923:AC:A	donor_loss	1.0000
17:5214924:C:CA	donor_gain	1.0000
17:5214924:CA:C	donor_gain	1.0000
17:5214924:CAA:C	donor_gain	1.0000
17:5214924:CAAG:C	donor_gain	1.0000
17:5214924:CAAGA:C	donor_gain	1.0000
17:5214994:CATTC:C	acceptor_gain	1.0000
17:5214996:TTC:T	acceptor_gain	1.0000
17:5214999:C:CC	acceptor_gain	1.0000
17:5214999:CTAGA:C	acceptor_loss	1.0000
17:5215000:T:G	acceptor_loss	1.0000
17:5221285:A:AC	donor_gain	1.0000
17:5221286:C:CT	donor_gain	1.0000
17:5221286:CT:C	donor_gain	1.0000
17:5223352:A:AC	donor_gain	1.0000
17:5223353:C:CC	donor_gain	1.0000
17:5223353:CAGA:C	donor_gain	1.0000
17:5214917:ATAC:A	donor_loss	0.9900
17:5214918:TACT:T	donor_loss	0.9900
17:5214995:ATTC:A	acceptor_gain	0.9900
17:5214997:TC:T	acceptor_gain	0.9900
17:5214998:CC:C	acceptor_gain	0.9900
17:5221279:CTACT:C	donor_loss	0.9900
17:5221280:TACTT:T	donor_loss	0.9900
17:5221281:ACTT:A	donor_loss	0.9900

AlphaMissense

949 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:5223420:A:G	W20R	0.975
17:5223420:A:T	W20R	0.975
17:5223375:C:G	G35R	0.966
17:5223421:G:C	F19L	0.964
17:5223421:G:T	F19L	0.964
17:5223423:A:G	F19L	0.964
17:5210842:C:G	D133H	0.954
17:5223381:C:G	G33R	0.945
17:5210840:A:C	D133E	0.942
17:5210840:A:T	D133E	0.942
17:5210845:C:G	D132H	0.940
17:5223374:C:T	G35D	0.939
17:5223407:G:T	A24D	0.938
17:5210841:T:A	D133V	0.937
17:5210844:T:A	D132V	0.932
17:5210841:T:G	D133A	0.924
17:5210848:A:G	Y131H	0.913
17:5210851:C:G	D130H	0.913
17:5210841:T:C	D133G	0.910
17:5214950:C:A	R86S	0.910
17:5214950:C:G	R86S	0.910
17:5223435:A:G	W15R	0.909
17:5223435:A:T	W15R	0.909
17:5223377:A:G	L34P	0.906
17:5214995:A:C	N71K	0.904
17:5214995:A:T	N71K	0.904
17:5223377:A:C	L34R	0.901
17:5223422:A:G	F19S	0.901
17:5210844:T:G	D132A	0.899
17:5210849:G:C	D130E	0.894

dbSNP variants (sampled 300 via entrez): RS1000372428 (17:5210262 T>A,G), RS1000374401 (17:5232037 C>A,T), RS1000481513 (17:5210049 T>A,C), RS1000572549 (17:5228431 G>C,T), RS1000583727 (17:5216250 T>C), RS1000591110 (17:5233886 C>G), RS1000743809 (17:5210434 A>G), RS1000750221 (17:5222572 A>C,G), RS1000828922 (17:5214427 G>T), RS1001084486 (17:5226738 A>C), RS1001111107 (17:5209002 A>G), RS1001130905 (17:5213311 A>G), RS1001173154 (17:5228767 T>C), RS1001185558 (17:5218226 A>G), RS1001428954 (17:5220516 A>C)

Disease associations

OMIM: gene MIM:614406 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): head and neck cancer (MONDO:0005627)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST002245_32	Alzheimer’s disease (late onset)	4.000000e-07
GCST007319_14	Alzheimer’s disease (late onset)	3.000000e-06
GCST007320_62	Alzheimer’s disease or family history of Alzheimer’s disease	9.000000e-10
GCST007321_29	Family history of Alzheimer’s disease	5.000000e-08
GCST009021_20	Alzheimer’s disease	1.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0009268	family history of Alzheimer’s disease

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6196105 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

1 potent at pChembl≥5 of 1 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.64	EC50	22.98	nM	CHEMBL6162522

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
(+)-JQ1 compound	decreases expression	2
GSK-J4	decreases expression	1
hydroxyhydroquinone	decreases expression, decreases reaction	1
4-aminobenzhydrazide	decreases expression, decreases reaction	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	1
Air Pollutants	affects expression, increases abundance	1
Air Pollutants, Occupational	decreases expression	1
Amiodarone	increases expression	1
Diethylhexyl Phthalate	decreases expression	1
Lipopolysaccharides	affects response to substance, increases expression, affects cotreatment, decreases expression	1
Nickel	decreases expression	1
Ozone	affects expression, increases abundance	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	increases expression	1
Zidovudine	affects cotreatment, increases expression	1
Okadaic Acid	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL6094971	Binding	Inhibition of SLP76 phosphorylation in human Jurkat cells incubated for 24 hrs by Western blotting analysis	Discovery of Novel PROTAC-Based HPK1 Degraders with High Potency and Selectivity for Cancer Immunotherapy. — J Med Chem

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00138827	PHASE4	COMPLETED	Mouth Care Regimes During Radiotherapy
NCT00158041	PHASE4	COMPLETED	Subcutaneous Amifostine Safety Study
NCT00198263	PHASE4	COMPLETED	Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer
NCT00333099	PHASE4	COMPLETED	INEC Study: Immuno-modulating Enteral Nutrition in Cancer
NCT00365508	PHASE4	COMPLETED	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
NCT00666978	PHASE4	COMPLETED	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
NCT00772681	PHASE4	COMPLETED	Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma
NCT00813631	PHASE4	UNKNOWN	The Effect on an Ionic Silver Dressing in Head and Neck Patients With Malignant Fungating Wound
NCT01317589	PHASE4	COMPLETED	Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective?
NCT01418118	PHASE4	COMPLETED	Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery
NCT01553032	PHASE4	COMPLETED	Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)
NCT02015650	PHASE4	TERMINATED	Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck
NCT02049112	PHASE4	COMPLETED	A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study
NCT02241083	PHASE4	COMPLETED	The Effect of Norepinephrine and Dopamine on Radial Forearm Free Flap Tissue Oxygen Pressure and Microdialysate Metabolite Measurements
NCT02241876	PHASE4	UNKNOWN	THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS
NCT02597582	PHASE4	COMPLETED	LigaSure Small Jaw® Versus Conventional Neck Dissection in Head and Neck Cancer Patients
NCT02622880	PHASE4	COMPLETED	Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer Patients
NCT02880072	PHASE4	COMPLETED	Absorption of Orally Ingested Phosphate in Refeeding Syndrome
NCT02926573	PHASE4	COMPLETED	Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients
NCT03607227	PHASE4	COMPLETED	Continous Popliteal Block for Microvascular Free Flap Reconstruction in Ear, Nose and Throat Surgery
NCT03714867	PHASE4	WITHDRAWN	Pre-Operative Pregabalin for Post-Operative Pain in Head and Neck Cancer Surgery
NCT04155008	PHASE4	TERMINATED	Nutrition and Pharmacological Algorithm for Oncology Patients Study
NCT04246697	PHASE4	COMPLETED	Multimodal Pain Study in Free Flap Patients
NCT04292990	PHASE4	UNKNOWN	Comparison of Transdermal Fentanyl and Morphine for Oral Mucositis Pain in Nasopharyngeal Cancer Patients
NCT04507035	PHASE4	UNKNOWN	Treating Locally Advanced Head and Neck Malignant Tumor With Anlotinib and Chemoradiotherapy
NCT04977271	PHASE4	WITHDRAWN	Mood Disorders in Head and Neck Cancer Patients
NCT05046028	PHASE4	COMPLETED	Individualization of Nutritive Sensory Support Of Radiation Therapy
NCT05055726	PHASE4	COMPLETED	Benzydamine Oromucosal Solution in Oral Mucositis (BOOM)
NCT06521697	PHASE4	NOT_YET_RECRUITING	Effects of Minimal-Flow Sevoflurane and Multimodal Analgesia in Head and Neck Cancer Surgery
NCT06734598	PHASE4	RECRUITING	Efficacy of Botox Injection of the Masticatory Muscles in Head &Neck Cancer Patients with Trismus After Radiotherapy
NCT06807034	PHASE4	ACTIVE_NOT_RECRUITING	Impact of the Oral Microbiota on Relapse in HNSCC Patients
NCT06879691	PHASE4	ACTIVE_NOT_RECRUITING	A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma
NCT07158164	PHASE4	RECRUITING	DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
NCT07189897	PHASE4	RECRUITING	Apixaban or Enoxaparin After Head and Neck Cancer Surgery
NCT00002476	PHASE3	COMPLETED	Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer
NCT00002496	PHASE3	COMPLETED	Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Cancer of the Larynx
NCT00002507	PHASE3	COMPLETED	Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer
NCT00002555	PHASE3	COMPLETED	High-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer
NCT00002654	PHASE3	COMPLETED	Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer
NCT00002659	PHASE3	UNKNOWN	Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer